[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sexual-dysfunction-male\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sexual-dysfunction-male":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100628368","priapus-pca-study-stereotactic-body-radiation-therapy-sbrt-and-androgen-deprivation-therapy-adt-impact-on-sexual-function-on-men-with-unfavorable-intermediate-risk-prostate-cancer-100628368",false,"NCT07460726","PRIAPUS-PCa Study: Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) Impact on Sexual Function on Men With Unfavorable Intermediate Risk Prostate Cancer","A Single Arm Prospective Study to Investigate the Impact of Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) on Sexual Dysfunction in Unfavorable Intermediate Risk Prostate Cancer","PRIAPUS-PCa","Inclusion Criteria:\n\n* Men aged 18-80 years with biopsy-proven UIR-PCa (National Comprehensive Cancer Network \\[NCCN\\] criteria: Gleason score 7 (4+3), PSA 10-20 ng\u002FmL, or clinical stage T2b-T2c)\n* Planned treatment with SBRT (36.25-37.5 Gy in 5 fractions) and ADT (6 months)\n* Baseline sexual function assessment available (International Index of Erectile Function \\[IIEF-5, also known as SHIM\\] score ≥ 12 or pre-selection erection status score of 1-3: erection insufficient for intercourse, sufficient but not optimal, or normal)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n* Written informed consent to participate.\n\nExclusion Criteria:\n\n* Prior pelvic radiotherapy, prostate surgery, ADT, or chemotherapy\n* Pre-existing severe sexual dysfunction (IIEF-5 score \\\u003C 12 or pre-selection erection status score of 0: no erection)\n* Hypogonadism at presentation (baseline testosterone below normal range)\n* Contraindications to SBRT or ADT\n* Metastatic disease, second malignancy, or previous malignancies.\n* Benign or malignant penile diseases.\n* Use of medications altering ejaculation (e.g., 5-alpha reductase inhibitors)\n* Psychiatric conditions affecting questionnaire completion or QoL assessment\n* Severe comorbidities affecting QoL assessments (e.g., advanced cardiovascular disease).","MALE","18 Years","80 Years",{"count":21,"type":22},130,"ESTIMATED","24 Months","OBSERVATIONAL","This study looks at how combined radiation and hormone therapy affects sexual function in men with a specific type of prostate cancer, before and after treatment.",[27,28,29],"Prostate Cancer (Adenocarcinoma)","Erectile Abnormalities","Sexual Dysfunction Male",[31,32,33,34],"Prostate cancer","sexual function","SBRT","ADT","NOT_YET_RECRUITING","2026-03-04",{"date":38,"type":39},"2026-03-10","ACTUAL",{"date":41,"type":22},"2026-03-16",{"date":43,"type":22},"2029-12-31",{"name":45,"class":46},"CancerCare Manitoba","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":47},"100465799","phase-1-umbilical-cord-derived-mesenchymal-stem-cell-vcell-1-for-male-patients-with-sexual-deficiency-100465799","NCT05345418","Umbilical Cord-Derived Mesenchymal Stem Cell (VCELL 1) for Male Patients With Sexual Deficiency","Evaluation of the Safety and Efficacy of Umbilical Cord-Derived Mesenchymal Stem Cell (VCELL 1) for Male Patients With Sexual Deficiency: A Phase I\u002FIIa Randomised Crossover Trial","Inclusion Criteria:\n\n* Males with sexual hormone deficiency aged 50 to 70 years\n* AMS score ≥ 27\n* IIEF \\\u003C 14\n* SQoL-M ≤ 87\n* and Testosterone ≤ 12 nMol\u002FL\n* Normal liver function (ALT, AST and Bilirubin are normal according to biological index of Vietnamese people).\n* Normal kidney function is usually according to the biological index of Vietnamese people.\n* No infection, HIV, HBV, active syphilis.\n* Must provide written informed consent.\n\nExclusion Criteria:\n\n* The patient had surgery to remove the gonads.\n* Patients with a history of cancer, or undergoing cancer treatment, or are positive for cancer screening tests including: PSA, AFP, Pepsinogen I, Pepsinogen II and erythrocyte smear test.\n\nThe patient is taking anti-rejection drugs.\n\n* Patients with malformations, malformations or tumors of the endocrine glands.\n* Endocrine impairment due to diabetes (HBA1c \\> 7) and other metabolic diseases.\n* Patients with active autoimmune disease or positive for antinuclear antibodies.\n* Patients with severe heart failure, severe renal failure, severe liver failure, severe respiratory failure, history of cerebral infarction, myocardial infarction, Alzeimer.\n* Patients with hypothyroidism.\n* The patient has an acute infection.\n* Patients with clinically significant coagulopathy or other hematological diseases.\n* History of allergy to anesthetics, anesthetics, antibiotics.\n* Patients who are using other hormone-improving drugs or supplements (including Sildenafil) in the last 2 weeks or want to continue using these drugs during the study period.\n* The patient is a smoker.","50 Years","70 Years",{"count":58,"type":22},158,"INTERVENTIONAL",[61,62],"PHASE1","PHASE2","Sexual functional deficiency affects largely the physical conditions, life and sexual quality of the patients. Hypogonadism affects about 4 to 5 million men in the US, and the incidence increases with age. In our recent phase I clinical trial, we have shown that intravenous adipose - derived MSC administration was safe in female and male patients with hormone deficiency. Post-transplantation sexual satisfaction was observed in all patients enrolled in this study. Testosterone levels in males increased significantly after transplantation and were maintained at high levels for up to 6 months before decreasing again at the 12-month follow-up. The aim of this clinical trial was to assess the safety and effectiveness of allogeneic administration of MSCs in middle-aged people with sexual functional deficiency.",[29],[29,66,67],"reproductive hormones","mesenchymal stem Cell","RECRUITING","2024-06-03",{"date":71,"type":39},"2024-06-04",{"date":73,"type":39},"2022-04-01",{"date":75,"type":22},"2025-12-30",{"name":77,"class":46},"Vinmec Research Institute of Stem Cell and Gene Technology"]